Loading
Virus-based Gene Therapy Research / CRISPR and Genetic Engineering · Journal article
Current Pharmaceutical Design · August 19, 2026
The material analysed did not support any firm read.
This is a narrative review article surveying the mechanisms, technological advances, and future potential of CRISPR-Cas9 gene editing in cancer therapy. It identifies conceptual opportunities and known barriers (off-target effects, delivery, ethics) but reports no original efficacy data, clinical outcomes, or comparative evidence to support current therapeutic use.
Narrative review.
CRISPR-Cas9 alters DNA sequences to inhibit oncogenes through base and prime editing, thereby suppressing tumor growth (mechanism described but not quantified) Key limitations identified: off-target effects, ethical concerns, and targeted delivery challenges restrict clinical applications Review explores strategies for precise delivery, improved targeting accuracy, and regulatory considerations for oncological CRISPR applications
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is a narrative review exploring mechanisms and prospects of CRISPR-Cas9 in cancer therapy without reporting clinical trial data, efficacy outcomes, or comparative evidence.
As stated by the source record.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Gene editing has enormous potential in biomedical fields, including cancer and personalized medicine. CRISPR-Cas9 is a gene-editing system in which the Cas9 enzyme, guided by RNA derived from short palindromic repeats, alters DNA sequences to inhibit oncogenes through base and prime editing, thereby suppressing tumor growth. Despite significant advancements in anticancer therapies, limitations such as off-target effects, ethical concerns, and challenges in targeted delivery restrict its potential clinical applications. In the present review, we explore the mechanisms of CRISPR-Cas9 gene editing, recent technological advancements, and prospects for cancer management. We also provide insights into strategies for precise delivery, improved targeting accuracy, and the regulatory considerations surrounding CRISPR-Cas9 for oncological applications. Additionally, this review examines the potential of CRISPR-Cas9 in personalized cancer therapy and discusses approaches to enhance tumor-specific targeting and facilitate clinical translation.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.